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The nucleotide NAADP was recently discovered as a second mes-
senger involved in the initiation and propagation of Ca2 signaling
in lymphoma T cells, but its impact on primary T cell function is still
unknown. An optimized, synthetic, small molecule inhibitor of
NAADP action, termed BZ194, was designed and synthesized.
BZ194 neither interfered with Ca2 mobilization by D-myo-inositol
1,4,5-trisphosphate or cyclic ADP-ribose nor with capacitative
Ca2 entry. BZ194 specifically and effectively blocked NAADP-
stimulated [3H]ryanodine binding to the purified type 1 ryanodine
receptor. Further, in intact T cells, Ca2 mobilization evoked by
NAADP or by formation of the immunological synapse between
primary effector T cells and astrocytes was inhibited by BZ194.
Downstream events of Ca2 mobilization, such as nuclear translo-
cation of ‘‘nuclear factor of activated T cells’’ (NFAT), T cell receptor-
driven interleukin-2 production, and proliferation in antigen-
experienced CD4 effector T cells, were attenuated by the NAADP
antagonist. Taken together, specific inhibition of the NAADP sig-
naling pathway constitutes a way to specifically and effectively
modulate T-cell activation and has potential in the therapy of
autoimmune diseases.
antagonism  nucleotide  second messenger  synthesis
Ca2 signaling is one of the essential signal transduction systemsinvolved in T-cell activation.Upon formation of immunological
synapses, a complex network of Ca2 signaling modules is activated
in a spatiotemporal fashion. One of the major mechanisms in-
volved, capacitativeCa2 entry viaOrai1/CRACM1 (1–4), requires
continuous Ca2 release from intracellular pools for activation.
Besides Ca2 release by D-myo-inositol 1,4,5-trisphosphate (InsP3,
ref. 5), we have shown that two additional secondmessengers, cyclic
ADP-ribose (cADPR; ref. 6) and NAADP (Fig. 1A; refs. 7–10) are
critically involved in the process of Ca2 release in T cells.
NAADP was discovered by Lee and coworkers as an impurity in
nicotinamide adenine dinucleotide phosphate (NADP) prepara-
tions and is the most powerful endogenous Ca2 mobilizing com-
pound known to date (11). Both plant and animal cells have been
shown to respond to application of NAADP (reviewed in refs.
12–14). A limited number of reports demonstrated that extracel-
lular stimulation increased intracellular NAADP concentrations,
being in accordance with a secondmessenger function for NAADP
(reviewed in refs. 15–17).
A controversial issue regardingNAADP is themolecular identity
of its receptor. Clearly, in sea urchin eggs, the characterization of
NAADP induced Ca2 release revealed that a receptor/channel
different from the InsP3 receptor or the ryanodine receptor (RyR)
is involved (11, 18). In addition, Lee’s group obtained evidence for
a non-ER Ca2 store sensitive to NAADP in stratified sea urchin
eggs (19) that was finally identified as a lysosomal compartment
(20–23). Recent evidence indicates that the novel NAADP recep-
tor on lysosomes is the Ca2 channel transient receptor potential,
mucolipin 1 (TRP-ML1; 24, 25). In contrast, data obtained by
reconstitution of RyR in artificial bilayers suggest direct activation
of RyR by NAADP (26, 27). In addition, NAADP-induced Ca2
signaling involving RyR was described for MIN6 cells (28), pan-
creatic acinar cells (29, 30), and human T cells (9, 10). In contrast
to the lysosomal store mentioned above, in those cells where RyR
involvement was demonstrated, the Ca2 pool sensitive to NAADP
appears to be the SR/ER or ER-related membrane systems like the
nuclear envelope rather than lysosomes (26, 27, 29, 31).
Over the last years, some of us have analyzed the NAADP
pathway in Jurkat T lymphocytes in detail, including formation of
NAADP (8), local and global Ca2 release via RyR (9, 10), and
identification of the NAADP sensitive Ca2 store residing within
the ER (31). However, the functional role of NAADP in primary
T cells has remained unclear due to the inability to specifically
interfere with this signaling pathway by means of chemical biolog-
ical tools. Here we report the synthesis and biological character-
ization of an optimized NAADP antagonist for T cells, termed
BZ194.
Results
A NAADP Antagonist Based on Nicotinic Acid. Microinjection of
NAADP into single Jurkat T cells induced robust Ca2 signaling as
described previously (7, 9, 10, 31). Co-injection of nicotinic acid, but
not of nicotinamide, greatly reduced Ca2 signaling induced by
NAADP (Fig. 1B), indicating that nicotinic acid derivatives might
be suitable for chemical biological intervention as NAADP antag-
onists and for possible drug design. Since NAADP is highly active
in Ca2 release, while the structurally related parent compound
NADP (Fig. 1A) is inactive (11), it is very likely to be the nicotinic
acid moiety that interferes with NAADP-mediated Ca2 signaling.
Indeed, since cellular uptake of the polar nicotinic acid is slow and
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thismolecule is obviously intracellularly channeled into biosynthesis
of nicotinamide adenine dinucleotide (NAD), we reasoned that
design of a membrane-permeant analogue should be a powerful
approach toward targeting the NAADP/Ca2 signaling pathway.
NAADP itself is clearly too polar to be a useful starting point for
any chemical design, but the nicotinic acid moiety is ideally based
from which to develop modified drug-like small molecule NAADP
modulators. Consequently, prototype nicotinic acid derivatives
were synthesized by alkylation of nicotinic acid using 2-bromo-
acetylamides as the alkylating agents. From a library of alkylated
nicotinic acid derivatives (representative examples are shown inFig.
S1A) the N-alkylated 8-carbon side chain derivative, 3-carboxyl-1-
octylcarbamoylmethyl-pyridinium (BZ194) emerged as a potent
antagonist of proliferation of effector T cells (Fig. S1B). Impor-
tantly, whenBZ194was co-injected into Jurkat T cells togetherwith
NAADP, both the initial Ca2 peak and the sustainedCa2 plateau
observed upon injection of NAADP were concentration-
dependently blocked resulting in an IC50 in the low micromolar
range (Fig. 1 C and D). Notably, BZ194 co-injected together with
the Ca2 mobilizing second messengers InsP3 or cADPR (Fig. 1E
and Fig. S2 A and B) did not inhibit their activity suggesting high
specificity of BZ194 toward the NAADP/Ca2 signaling pathway.
RyR1 Activation by NAADP. Previously, we have presented evidence
for NAADP targeting the RyR (9, 10), including use of single
channel recordings (26). To extend these results, we used highly
purified RyR1 (Fig. 2A), and analyzed high-affinity [3H]ryanodine
binding, which is proportional to channel opening (32). NAADP
significantly accelerated the association of [3H]ryanodine to the
purified RyR1 (Fig. 2B). While BZ194 had no effect on the basal
[3H]ryanodine binding, the NAADP-induced increment in radio-
ligand binding was completely abrogated. Importantly, the disso-
ciation of [3H]ryanodine was not influenced by BZ194 (Fig. 2C)
whereas the dissociation from NAADP preactivated RyR1 was
significantly accelerated, indicating an allosteric regulation. The
basal equilibrium binding was not significantly altered by increasing
concentrations of BZ194 (Fig. 2D). However, [3H]ryanodine bind-
ing stimulated by NAADP was antagonized by BZ194 in a con-
centration-dependent manner (Fig. 2D). The IC50 value was com-
parable with that observed for Ca2 release inhibition in the native
cellular system (Fig. 1D). Hence, these results are indicative of
direct targeting of RyR1 by both NAADP and BZ194.
Antagonism of Ca2 Signaling in Primary T Cells by NAADP Antagonist
BZ194. Having demonstrated specific antagonism of NAADP ef-
fects at the purified RyR1 and in the model T cell line Jurkat,
primary myelin-basic-protein-reactive rat T cells (TMBP cells) were
used to study the role ofNAADPactivation in effectorT cells. TMBP
cells express bothRyR1andRyR3, althoughRyR3 to a lesser extent
(Fig. 3A). RyR1 showed a significant co-localization with an ER
marker, while RyR2 was not detected (Fig. 3A).
BZ194-type compounds with varying lengths and types of side
chains R1 and/or R2 (Fig. S1A), were tested with intact TMBP cells
using antigen-induced proliferation as read-out (Fig. S1B). Using
iterative exploration of substituents the single octyl side chain of
BZ194 proved to be most suitable for membrane permeability and
neither a longer side chain, for example, 10 carbon atoms in BZ71,
nor a lack of side chain in CMA008 had any effect on TMBP cell
proliferation (Fig. S1A andB). Interestingly, the other active analog
identified, the disubstituted BZ52, possesses the same number of
side chain carbon atoms, but distributed over 2 centers. BZ194
blocked Ca2 signaling in intact TMBP cells upon stimulation with
the specific antigen. Using astrocytes pulsed with MBP, Ca2
signaling was recorded upon formation of the immunological
synapse (Fig. 3B). While presentation of MBP by the astrocytes
resulted in substantial Ca2 signaling, reaching a plateau phase
within about 4 min, BZ194 significantly diminished this response
(Fig. 3 B and C). Analysis on a single-cell level revealed that
treatment with BZ194 significantly decreased the percentage of T
cells showing high Ca2 responses. WithMBP as antigenic protein,
21 out of 30 cells showed Ca2 signals 200 nM, whereas upon
BZ194 preincubation Ca2 signals200 nMwere observed in only
17 out of 31 cells. If only Ca2 signals 300 nM were taken into
account, with MBP as antigenic protein, 19 out of 30 cells re-
sponded, while BZ194 decreased the number of responding cells to
10 out of 31. Ca2 signaling of TMBP cells evoked by anti-CD3
Fig. 1. Nicotinic acid and its derivative BZ194 inhibit NAADP-mediated Ca2 signaling in T cells. (A) Structures of NAADP and NADP. (B) NAADP-induced
Ca2 signaling in T cells is inhibited by nicotinic acid. Jurkat T cells were loaded with Fura-2/AM and were microinjected with 100 nM NAADP, 100 nM NAADP
plus 1 mM nicotinamide, or 100 nM NAADP plus 1 mM nicotinic acid, or intracellular buffer. Free cytosolic Ca2 ([Ca2]i) was measured. Mean data of 4 –12
experiments are shown (Upper). The bar chart (Lower) summarizes the data (Ca2 peak and Ca2 plateau; means  SEM., n  4 – 12; *, P  0.05; ns, not
significant). (C) Inhibition of NAADP-induced Ca2 signaling upon co-injection with BZ194. Jurkat T cells were co-injected with 100 nM NAADP and
increasing concentrations of BZ194. Mean data of 5–13 experiments are shown. (D) Concentration-response curve of NAADP-induced Ca2 signaling upon
microinjection with BZ194 (mean  SEM, n  5–13; *, P  0.05). (E) BZ194 does not directly interfere with InsP3- or cADPR-mediated Ca2 release. Jurkat
T cells were loaded with Fura2/AM. Thereafter, single cells were co-injected with 1 mM BZ194 and either NAADP (100 nM), InsP3 (4 M), or cADPR (100
M), and Ca2 signaling was recorded. Relative values are shown as percentages of NAADP-induced [Ca2]i. Data represent means  SEM, n  5–13; *,
P  0.05; ns, not significant.








monoclonal antibody, and subsequent crosslinking of the primary
antibody was also sensitive to BZ194. Both the initial Ca2 peak
and the sustained Ca2 plateau were reduced in a concentration-
dependent fashion with the plateau being more sensitive com-
pared with the initial peak (Fig. 3 D and E). The antagonistic
effect of BZ194 required preincubation periods (Fig. 3F), indi-
cating moderate membrane permeancy and/or activation of drug
export systems.
Capacitative Ca2 entry was not inhibited by BZ194 since Ca2
signaling induced by thapsigargin in TMBP cells was unaffected (Fig.
3 G and H). Taken together, our data suggest a crucial role for
NAADP as trigger of Ca2 signals during the process of immuno-
logical synapse formation.
NAADP Antagonist BZ194 Suppressed Downstream Events of Ca2
Signaling. Calcium signaling in T cells activates Ca2/calmodulin
dependent phosphatase calcineurin leading to ‘‘nuclear factor of T
cells’’ (NFAT) dephosphorylation and translocation into the nu-
cleus. BZ194 significantly reduced nuclear translocation of NFAT
following combined stimulation of rat TMBP cells with anti-CD3 and
anti-CD28 antibodies (Fig. 4 A and B).
Furthermore, BZ194 efficiently suppressed antigen-induced pro-
duction of the major T cell cytokine IL-2, as determined on the
mRNA and protein levels (Fig. 4 C and D). Importantly, BZ194-
mediated regulation of IL-2 levels was reversible. Re-stimulation of
the suppressed T cells in the absence of BZ194 led to complete
reconstitution of the original cytokine profile (Fig. S3). In a similar
fashion as for rat T cells, in human MBP-specific T-cell clones a
decrease in IL-2 mRNA, IL-2 production and proliferation was
observed upon preincubation with BZ194 (Fig. S4).
The NAADP antagonist suppressed antigen-induced T-cell pro-
liferation at concentrations higher than 50 M. As expected, the
highly polar and membrane impermeable parent compound nico-
tinic acid was ineffective (Fig. S1B). Non-stimulated TMBP cells
tolerated prolonged treatment (48 h) with BZ194; furthermore, T
cells which had previously been suppressed by BZ194 remained
responsive to their antigen, when re-challenged with antigen-
pulsed, antigen-presenting cells (APCs) after wash-out of BZ194
(Fig. S5).Moreover, BZ194 treatment 48 h after stimulation did not
impair T-cell proliferation and did not induce increased cell death
(Fig. S5). Together with the microinjection (Fig. 1 B–E) and the
[3H]ryanodine binding results (Fig. 2), these data indicate very
specific targeting of RyR1 since (i) wash-out of BZ194 reverted the
inhibition, and (ii) late stages of T-cell activation (48h) were
unaffected by addition of BZ194. This interpretation was further
substantiated by directly demonstrating that BZ194 did not affect
cellular signaling cascades beyond Ca2 signaling. Bypassing early
Ca2 signaling by stimulating TMBP cells with Ca2 ionophore
ionomycin either in combination with anti-CD3/anti-CD28 anti-
bodies or with phorbol ester (PMA) rendered the T cells non-
susceptible to BZ194 inhibition (Fig. 4E). Similar inhibition of
proliferation by BZ194 treatment was observed in ovalbumin and
S100-specific rat T cells (Fig. S6).
Discussion
Recent reports on the role of Ca2 signaling in activation of T cells
indicate a complex network involving NAADP as initial Ca2
trigger (7–10, reviewed in ref. 17). Here we report that the nicotinic
acid residue of NAADP is suitable as a starting point for the
development of NAADP antagonists. In sea urchin eggs, the
2-phospho-group of the ribose bound to the adenine-linked ribose,
the 6-NH2 group of adenine and the nicotinic acid moiety were
identified as important structural elements for Ca2 release (33).
Since these 3 structural moieties are distributed over the whole
NAADPmolecule, it was deemed very difficult to design a potential
antagonist molecule comprising alterations in all 3 structural ele-
ments. Thus, we started with simple N-alkylated analogues of
nicotinic acid to which lipophilic groups to enhance membrane
permeability were covalently bound. Additionally, we explored
other substitutions around the aromatic nucleus to optimize activ-
ity. A range of potential ligands was synthesized to gain the optimal
balance between cellular permeability, activity, and physicochem-
ical properties. In structure-activity studies, we found that little
variation beyond a moderate-sized hydrophobic side chain was
tolerated by T cells. In fact, the 8 carbon-side chain analog BZ194
was effective with an IC50 around 100 M. This extra hydropho-
bicity in BZ194 can also be distributed over 2 substituents on
nitrogen atoms giving a similar effect in BZ52 and thus is consistent
without further optimization. In contrast to BZ194 and BZ52,
BZ23, an analog with a substituted aromatic side chain, en-
hanced proliferation of TMBP cells. The molecular mechanism
underlying this interesting observation will be the subject of
further experiments.
One obvious concern in using pharmacological compounds is the
question of their specificity. To this end, we excluded that BZ194
affects the other known Ca2-mobilizing pathways, that is InsP3- or
cADPR-dependent Ca2 release, or capacitative Ca2 entry. Fur-
thermore, (i) bypassing inhibition of NAADP signaling by Ca2
ionophore, (ii) reversibility of inhibition of proliferation upon
wash-out of BZ194, and (iii) lack of effect of BZ194 addition at later
time points of T-cell activation altogether strongly suggest high
specificity of the drug used. Finally, we also ensured that BZ194
does not block physiological Ca2 signaling via different mecha-
nisms in other cell types, for example, in electrically paced mouse
cardiac myocytes or human HeLa cells stimulated via G protein
coupled muscarinic acetylcholine receptors.
Fig. 2. Targeting of NAADP RyR1 interaction by BZ194. (A) Silver-stained gel
demonstrating the purity of RyR1 preparation. (B) Kinetics of NAADP-induced
association of [3H] ryanodine to the purified RyR1 at 30 °C. Specific [3H]ryano-
dine binding in the absence (control) or presence of 300 nM NAADP; BZ194
(100 M) was combined with both control and NAADP experiments. Asterisk
(*) denotes statistical significance of NAADP over control, cross (#) that of
BZ194 plus NAADP over NAADP alone. Data are mean SD. (n 4). (C) After
2 h of association, dissociation of bound [3H] ryanodine (20 nM) was triggered
by 20 M cold ryanodine (ry) in the absence or presence of 300 nM NAADP or
100 M BZ194 (BZ) at 30 °C. Data are mean  SD. (n  4). (D) Inhibition of
NAADP-stimulated [3H]ryanodine binding to RyR1 by increasing concentra-
tions of BZ194 after 2 h at 30 °C. Data are mean  SEM (n  2–14).
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Recently, 1-carbamoylmethyl-3-carboxy pyridinium iodide (ab-
breviated CMA008; see Fig. S1 A and B) was shown to antagonize
NAADP effects in sea urchin eggs and murine pancreatic acinar
cells (34). Although this analog is structurally related to BZ194, no
inhibitory activity in T cells was observed. This non-sensitivity of T
cells vs. sensitivity of pancreatic acinar cells reflects the different
nature of the target Ca2 store and the NAADP receptor involved.
While a novel NAADP-sensitive channel has been proposed for
those cell types with acidic stores sensitive to NAADP (20–25),
strong evidence for RyR1 as NAADP target was obtained in T cells
sinceNAADPmodulated high-affinity [3H]ryanodine binding. This
in turn reflects RyR1 channel opening, as the radioligand binds to
the open conformation of the ion channel (32, 35–37). Importantly,
the BZ194 concentrations needed to suppress NAADP induced
Ca2 release in Jurkat T lymphocytes (Fig. 1D) equal that needed
to prevent NAADP stimulated [3H]ryanodine binding (Fig. 2B).
Thus, these data suggest that the RyR1 is the primary target for
BZ194.RyR3 is expressed to a lesser extent in effector T cells. Gene
silencing experiments in Jurkat T cells indicate that RyR3 is
targeted by cADPR (38). However, defining the precise interaction
between cADPR and any RyR subtype, as shown in Fig. 2 of this
report for NAADP and highly purified RyR1, requires further
extensive experiments. Alternatively proposed NAADP targets,
such as TRP-ML 1 (24, 25) that are localized to lysosomes, do not
appear to play a major role in T cells since the ER rather than
lysosomes are involved in NAADP mediated Ca2 signaling in T
cells (31).
The present study complements published models on temporal
events of Ca2 release. We show here that NAADP via RyR1
activation acts as the initializing trigger, which controls furtherCa2
release events by supplying local Ca2 signals for Ca2 induced
Ca2 release to amplify InsP3- and cADPR-induced Ca2 release.
NAADPmediated Ca2 release starts rapidly within a few seconds
upon TCR/CD3 ligation (8). By contrast, InsP3- and cADPR-
mediated releases appear within a few minutes (39) or within tens
of minutes, respectively (6). A possible reason for this complex
regulatory Ca2 release network may be the need for temporal
checkpoints, at which the T cell, based upon the input via the
TCR/CD3 complex and diverse co-receptors, can control whether
to proceed with activation or not (40). The decision whether to
continue or to stop Ca2 signaling may ultimately result in cell
proliferation and exertion of effector functions, or it may drive the
T cell into a state of unresponsiveness or cell death. The NAADP/
Ca2 signaling pathway seems to control this decision, since ex-
pression of the major cytokine involved in T cell proliferation, IL-2,
depends on a full, NAADP-initiatedCa2 response. If theNAADP
pathway is blocked by specific inhibitors, Ca2 signaling is only
partially activated. Therefore, it does not provide a sufficient
long-lasting increase in the free cytosolic Ca2 concentration to
allowCa2/calmodulin- and calcineurin-dependent translocation of
NFAT into the nucleus (41).
Fig. 3. RyR expression and antagonism of Ca2 signaling in rat MBP-specific effector T cells. (A) Expression of RyR subtypes in effector T cells. Immunofluorescence
for RyR1 to 3 (red) and the endoplasmatic reticulum marker protein disulphide isomerase (PDI, green). (Scale bar, 10 m.) (B) Suppression of Ca2 signaling in
Fura2-loaded TMBP cells stimulated in the presence of MBP-pulsed astrocytes. Rat F10 astrocytes with up-regulated MHC II expression were pulsed with MBP. TMBP cells,
either preincubated with BZ194 (2 mM, MBP  BZ194) or left untreated (MBP), were loaded with Fura-2/AM and added to the astrocytes. In control experiments,
astrocytes were not pulsed with MBP (control). Time point 0 was defined as first visible contact between a T cell and an astrocyte. Ca2 imaging was performed as
detailed in SI Methods. (B) shows a representative experiment with T cells highlighted by white lines in the brightfield images. (Scale bar, 5m.) (C) Mean global [Ca2]i
data from 14 (control: no MBP), 30 (MBP pulsed astrocytes), or 31 (MBP pulsed astrocytes plus T cells preincubated with BZ194) T cells are displayed. (D) Resting rat TMBP
cells were loaded with Fura2/AM and cell suspension measurements were carried out as described in Methods. Arrows indicate the addition of CD3 or crosslinking
(X) antibodies. Cells were preincubated with 500 M BZ194 overnight. (E) Concentration-response curves summarizing data from (D) (transient Ca2 peak and Ca2
plateau;meanSEM,n8–9). (F)EffectofBZ194preincubationtimeonCa2 signaling(meanSEM,n8–9). (G)Cellswerepreincubatedwith1mMBZ194overnight
and thapsigargin (1 mM, arrow) was added to induce capacitative Ca2 signaling; mean data SEM (n 9) are summarized in H. *, P 0.05 according to Student’s
t test; ns, not significant.








By establishing highly specific NAADP antagonists, we demon-
strate here that the NAADP/Ca2 pathway is critically involved in
early activation events of antigen-specific CD4 effector T cells.
NAADP antagonist BZ194 blocked the NAADP stimulated RyR1
Ca2 release and, as a secondary and indirect effect, all downstream
Ca2 signaling events depending on initial trigger Ca2 as co-
agonist were diminished. Thereby, NAADP antagonist BZ194
specifically interfered with the interactions of effector T cells with
APCs. Importantly, while down-modulating Ca2 signaling and
effector reactions of T cells, BZ194 did not show any major
unspecific effects. This may in part be explained by the virtual
absence of effects of BZ194 on basal equilibrium [3H]ryanodine
binding or dissociation kinetics (Fig. 2). BZ194 is thus an inhibitor
of the RyR1, which accesses the ion channel in the presence of
NAADP, implying that channel opening is necessary for its inhib-
itory action. The fact that BZ194 had virtually no inhibitory effect
on basal binding (Fig. 2B andD) supports this assumption. In terms
of potential clinical usage such a mechanism of action may result in
less effects on the basalRyR1 activity, but increased inhibition if the
RyR1 is activated. Thus, one may assume that side effects by such
a mechanism of action could be reduced compared with a state-
independent inhibitor of the RyR1.
Therefore, the involvement of the NAADP/Ca2 signaling path-
way in a primary T-cell model relevant for the pathogenic context
of T cell-mediated autoimmunity has been demonstrated in vitro
using a purpose-designed and optimized synthetic small molecule
antagonist. The use of suchNAADPantagonists in the correspond-
ing animal model of experimental autoimmune encephalomyelitis
(EAE) is the subject of ongoing investigations. Treatment with
BZ194 in vivo was found to significantly ameliorate clinical disease.
Thus, this approach may result in additional therapeutic agents for
treating autoimmune diseases such as multiple sclerosis.
Methods
Materials. NAADP was supplied by Sigma. cADPR and InsP3 were obtained from
Biolog. All reagents and solvents were of commercial quality and were used
directly unless otherwise described.
Synthesis of 3-Carboxy-1-octylcarbamoylmethyl-pyridinium Bromide (BZ194).
For synthesis, nicotinic acid (1.62 mmol) and 2-bromo-N-octylacetamide (1.62
mmol) were dissolved in dry dimethylformamide (DMF, 4 mL) and the reaction
solution was heated at 65 °C overnight in the dark. DMF was evaporated in
vacuo and the resulting residue was dissolved in a small amount of methanol.
The crude compound was precipitated by dropwise addition of ether.
3-Carboxy-1-octylcarbamoylmethylpyridinium was further purified by flash
column chromatography (0–10% methanol against dichlormethane) and was
crystallized in methanol and acetone. The compound exhibited spectroscopic
and analytical properties commensurate with its structure using standard
techniques as detailed in the SI Methods.
High-Affinity [3H]Ryanodine Binding. RyR1 was purified from rabbit skeletal
muscle (42). Purity of the RyR1 preparation was controlled by SDS/PAGE and silver
staining (43). High-affinity [3H]ryanodine binding was carried out with 7.5–20g
purified RyR1, which was incubated for the indicated times at 30 °C in a buffer
containing 20 mM Hepes (pH 7.4), 140 mM KCl, 50 mM NaCl, 2.5% phosphatidyl
choline, 7 mM CHAPS, and 20 nM [3H]ryanodine supplemented by protease
inhibitors (1 M leupeptin, 1 M aprotinin, and 100 M Pefablock). The free
calcium concentration was adjusted to 6 M by ratio of CaCl2 and EGTA. The
reactions were terminated by filtration. Specific binding was determined by
subtraction of nonspecific binding in the presence of 20 M ryanodine (42).
Generation and Culturing of T Cells. Jurkat lymphoma T cells (clone JMP) were
cultured as described previously (43). Rat antigen-specific T cell clones were
obtained from lymph node preparations of immunized Lewis rats. Stimulation,
expansion, and culture of specific rat T cells were conducted under conditions as
described (44). Details concerning generation of MBP-specific CD4 T cells (TMBP)
retrovirally engineered to express the marker gene EGFP are provided in the SI
Methods.
Cytosolic Ca2 Measurements. Both Jurkat T lymphoma and rat TMBP cells were
loaded with Fura-2/AM (Calbiochem) as described (44) and kept in the dark at
room temperature until use. Intracellular Ca2 ([Ca2]i) was determined in sus-
pensionsofFura-2-loadedratTMBP cellswhichhadbeenpreincubatedwithBZ194
or DMSO at the indicated concentrations for at least 8 h in a Hitachi F-2000
fluorometer as described previously (46). More detailed information about the
ratiometric Ca2 measuring method is provided in the SI Methods.
Microinjections. Intracellular injections were carried out as described previously
(7, 9, 10, 31). More detailed information is provided in the SI Methods.
Fig. 4. NAADP signaling is essential for efficient activation of antigen-specific
effector T cells. (A) BZ194 reduces NFAT-1 nuclear translocation. Immunocyto-
chemistry of BZ194-treated or control (DMSO- treated) TMBP cells 0, 30, or 60 min
after stimulation with CD3/CD28 antibodies. Red, DAPI staining; green, NFAT-1
or isotype control staining. (Scale bars, 10 m.) Representative data of 3 inde-
pendent experiments are shown. (B) Quantification of NFAT-1 nuclear translo-
cation, expressed as percent of cells. Values respresent means SD, data from 3
independentexperiments includingat least150cellspercounting.Pvalues:*,P
0.05;**, P0.01. (C–E) BZ194 suppresses activation-induced IL-2 expression in rat
and human TMBP cells. (C) Quantitative PCR of rat TMBP cells challenged with
control antigen- (OVA, white) or MBP- (black) pulsed APCs in the presence of
vehicle (control), 0.5 or 1 mM BZ194. mRNA was extracted 48 h after stimulation.
Values are normalized to  actin mRNA. Representative data of 3 independent
experiments are shown. All differences are statistically significant (P value, P at
least  0.05). (D) IL-2 protein release of TMBP cells 48 h after stimulation, deter-
mined by ELISA. Values represent means SD of triplicate measurements. Rep-
resentative data of at least 2 independent experiments are shown. *, P 0.0001.
(E) BZ194 blocks antigen-induced T cell proliferation, but does not interfere with
T-cell activation cascades beyond Ca2 signaling. TMBP cells incubated with the
indicated amounts of BZ194 were stimulated with CD3/CD28 antibodies (black
bars), PMA/ionomycin (white bars) or CD3/CD28 antibodies ionomycin (gray
bars). TMBP cells reactivity was determined by [3H]dT incorporation 2 d later.
Proliferation is indicated as percent of control (no BZ194 treatment; CD3/CD28
stimulation: 6445  475 cpm; CD3/CD28  ionomycin stimulation: 6624  320
cpm; PMA/ionomycin stimulation: 5264 521cpm). Data represent means SD
of measurements from 5 independent experiments. *, P 0.01.
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Proliferation Assays of Cultured T Cells. Antigen-specific rat T cells (TMBP and
TOVA) were co-cultured for 48 h in 96-well plates (in DMEM 1% rat serum) with
irradiated professional thymic APCs as previously described (45), in presence of
specific or control antigen (10g/mL MBP or OVA) and BZ194 in DMSO or DMSO
alone. Amplification of TMBP-GFP cells was measured by cytofluorometry. Their
numbers were determined in relation to a known absolute number of added
phycoerythrin-labeled plastic beads (Becton Dickinson). The amplification rate
was calculated in relation to the TGFP cell numbers at day 0. Alternatively, [3H]-
2-deoxy-thymidine ([3H]dT; 2 Ci/mmol; Amersham) incorporation was used to
evaluate proliferation. Radioactivity was determined as described (47). More
detailed information about proliferation assays in rat T cells is provided in the SI
Methods.
Quantitative PCR and ELISAs.Detailed information is provided in the SI Methods.
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